Loading...
In the randomized CURE trial, patients with non-ST-segment-elevation acute coronary syndrome (ACS) had a 20% lower 9-month composite rate of cardiovascular death, nonfatal MI, or stroke with clopidogrel than with placebo (Journal Watch Cardiology Sep 28 2001). In this retrospective analysis of CURE, researchers used the TIMI risk score to assess clopidogrel's benefit in low- (score, 0-2), intermediate- (3-4), and high- (5-7) risk subgroups. Each of the 7 risk predictors that constitute the score was similarly prevalent in the placebo and clopidogrel groups, and all 9-month outcomes increased proportionally with increasing risk in the total study group.
Compared with placebo, clopidogrel was associated with a significantly lower incidence of …